Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis-Reference-Cited by-同舟云学术

Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis

Published:2022-07-22 Issue:11 Volume:57 Page:2652-2658
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Causer Adam J.¹²,Shute Janis K.³,Cummings Michael H.⁴,Shepherd Anthony I.¹,Wallbanks Samuel R.¹,Pulsford Richard M.⁵,Bright Victoria²,Connett Gary²⁶,Saynor Zoe L.¹²^ORCID

Affiliation:

1. School of Sport, Health and Exercise Science, Faculty of Science and Health University of Portsmouth Portsmouth UK

2. Cystic Fibrosis Unit, University Hospital Southampton NHS Foundation Trust Southampton UK

3. School of Pharmacy and Biomedical Sciences, Faculty of Science and Health University of Portsmouth Portsmouth UK

4. Department of Diabetes and Endocrinology Queen Alexandra Hospital Portsmouth UK

5. Sport and Health Sciences, College of Life and Environmental Science University of Exeter Exeter UK

6. National Institute for Health Research, Southampton Biomedical Research Centre, Southampton Children's Hospital Southampton UK

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.26078

Reference29 articles.

1. State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy

2. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

3. VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

4. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

5. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The long-term effect of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study;BMC Pulmonary Medicine;2024-05-28

2. Changes in exercise capacity in people with Cystic Fibrosis after one year of Elexacaftor/Tezacaftor/Ivacaftor treatment – A Danish prospective cohort;Journal of Cystic Fibrosis;2024-05

3. Longitudinal Evaluation of Physical Fitness in Adults with Cystic Fibrosis in the Era of CFTR-Modulating-Therapies;Research Quarterly for Exercise and Sport;2024-03-13

4. One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis;Heliyon;2024-03

5. Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor;Frontiers in Sports and Active Living;2024-02-23